Antiretroviral drug therapy alters the profile of human immunodeficiency virus type 1-specific T-cell responses and shifts the immunodominant cytotoxic T-lymphocyte response from gag to pol

• Autor(a) principal: Karlsson, A. C.
• Data de Publicação: 2007
• Outros Autores: Chapman, J. M., Heiken, B. D., Hoh, R., Kallas, Esper Georges [UNIFESP], Martin, J. N., Hecht, F. M., Deeks, S. G., Nixon, D. F.
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Repositório Institucional da UNIFESP
• Texto Completo: http://dx.doi.org/10.1128/JVI.00779-07; http://repositorio.unifesp.br/handle/11600/30057

Antiretroviral drug therapy and cytotoxic T lymphocytes (CTL) both exert selective pressures on human immunodeficiency virus type 1, which influence viral evolution. Compared to chronically infected, antiretroviral-untreated patients, most chronically infected, treated patients with detectable viremia lack a cellular immune response against the Gag 77-85(SL9) epitope but show a new immunodominant response against an epitope in protease PR 76-84. Hence, mutations induced by antiretroviral therapy likely alter the profile of epitopes presented to T cells and thus the direction of the response. the consequences of dual pressures from treatment and CTL need to be considered in monitoring of drug therapy.